Patents by Inventor Jong-Phil Kang

Jong-Phil Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabilized vitamin C derivatives having a peptide molecule, preparation method thereof, and composition containing the same
    Patent number: 8829044
    Abstract: The present invention relates to a stabilized vitamin C derivative with a peptide molecule linked to vitamin C or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a composition containing the same.
    Type: Grant
    Filed: September 5, 2006
    Date of Patent: September 9, 2014
    Assignee: Peotron Co. Ltd.
    Inventors: Jong-Il Park, Heung-Jae Kim, Dong-Won Kim, Chae-Jin Lim, Jong-Phil Kang, Kyeong-Yong Park, Seok-Jeong Yoon, Seon-Deok Kwon, Ho-Il Choi
  • Stabilized bitamin c derivatives having a peptide molecule, preparation method thereof, and composition containing the same
    Publication number: 20100331260
    Abstract: The present invention relates to a stabilized vitamin C derivative with a peptide molecule linked to vitamin C or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a composition containing the same.
    Type: Application
    Filed: September 5, 2006
    Publication date: December 30, 2010
    Applicant: Peptron Co.Ltd.
    Inventors: Jong-II Park, Heung-Jae Kim, Dong-Won Kim, Chae-Jin Lim, Jong-Phil Kang, Kyeong-Yong Park, Seok-Jeong Yoon, Seon-Deok Kwon, Ho-Il Choi
  • BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME
    Publication number: 20100021480
    Abstract: This invention relates to a technology of modifying low-molecular-weight bioactive substances with short in vivo half-life and low stability in order to achieve a stable and efficient in vivo delivery thereof. More specifically, the present invention relates to a stable bioactive substance-blood protein conjugate, wherein a low-molecular-weight bioactive substance is ex vivo conjugated with a specific functional group on a blood protein through a reactive group, the low-molecular-weight bioactive substance is available as a drug for treatment and prevention in mammals including human and selected from the group consisting of a natural substance; and a method of a stable and efficient in vivo delivery of the low-molecular-weight bioactive substance based on the use of the bioactive substance-blood protein conjugate.
    Type: Application
    Filed: October 27, 2006
    Publication date: January 28, 2010
    Applicant: PEPTRON CO., LTD
    Inventors: Jong-Il Park, Min-Gyu Soung, Heung-Jae Kim, Chae-Jin Lim, Jong-Phil Kang, Ho-Il Choi